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A head and neck radiologist re-evaluated all MRIs, and the 
imaging findings were compared with histopathology after 
neck dissection. In the cohort of 39 patients, preoperative 
MRI showed concordance with histopathology for Levels II 
and V as follows: sensitivity of 94 and 67%, specificity of 
20 and 91%, positive predictive value of 56 and 75%, and 
negative predictive value of 75 and 87%, respectively. In 
PTC, MRI demonstrated fairly high specificity and negative 
predictive value for Level V metastasis, and future studies 
are needed to verify our results to omit prophylactic dissec-
tion of this level. Routine dissection of Level II in patients 
with regionally metastatic PTC needs to be considered, as 
MRI showed low specificity.
Keywords Papillary thyroid carcinoma · Lateral neck 
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Introduction
Papillary thyroid carcinoma (PTC) accounts for approxi-
mately 75% of all thyroid malignancies and more than 90% 
of differentiated thyroid carcinomas [1, 2]. Primary treat-
ment of PTC consists of surgery, typically total thyroidec-
tomy with or without central lymph node dissection, adapted 
radioiodine ablation and postoperative TSH suppression [1, 
3, 4]. PTC carries an excellent prognosis due to the slow 
growth and minimally invasive behavior with survival rates 
over 90% [5–7]. However, lymph node metastasis (LNM) 
in PTC is relatively common, as seen in 50–90% of patients 
[1, 3, 5, 8]. LNMs impact overall patient survival especially 
in patients over 45 years of age [9, 10]. Furthermore, LNMs 
in the lateral neck seem to increase the risk for locoregional 
recurrences and distant metastases [8], emphasizing the 
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noma (PTC) with lateral lymph node metastasis is surgery, 
but the extent of lateral neck dissection remains undefined. 
Preoperative imaging is used to guide the extent of surgery, 
although its sensitivity and specificity for defining the num-
ber and level of affected lymph nodes on the lateral neck 
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operative magnetic resonance imaging (MRI) in predict-
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importance of detailed preoperative evaluation in the pri-
mary treatment setting.
High-resolution ultrasound (US) and magnetic resonance 
imaging (MRI) are valuable in preoperative diagnostics of 
thyroid carcinoma [2, 11]. US is sensitive in the evaluation 
of the neck, and with the possibility of simultaneous nee-
dle biopsies [11]. However, US has suboptimal accuracy in 
assessing the levels of LNMs, especially for Levels II and 
V [12]. In comparison with US, MRI is superior especially 
in assessing extensive or bulky neck lymphadenopathy in 
the mediastinum or paratracheal, parapharyngeal, and ret-
ropharyngeal regions when experience in interpreting US 
is insufficient [13]. However, in the most recent guidelines 
from the American Thyroid Association (2015), only US is 
recommended for the routine evaluation of the neck prior 
surgery for differentiated thyroid carcinomas [13].
Although comprehensive neck dissection (ND) seems to 
decrease recurrences on the neck, the extent of ND needed 
in patients with PTC with LNM remains unclear [8, 14]. As 
current data on the role of MRI in demonstrating the levels 
of lateral neck metastases are limited, we assessed correla-
tion of MRI findings with histopathology, focusing on the 
accuracy of preoperative MRI in determining the requisite 
ND levels.
Materials and methods
All patients, who underwent lateral ND for preoperatively 
cytologically and/or radiologically confirmed LNM of PTC 
at the Department of Otorhinolaryngology—Head and 
Neck Surgery, Helsinki University Hospital, Helsinki, Fin-
land, from January, 2013 to February, 2016, were included 
in the study. The referral area comprises a population of 
1.6 million. Only patients with a diagnostic preoperative 
MRI and without any previous lateral neck operation were 
included. At our institution, we prefer MRI instead of com-
puted tomography (CT) in this patient population to avoid 
radiation exposure and to show possible increased T1 signal 
intensity.
Preoperative MRI was often used to help in defining the 
levels to be included in lateral ND. Still, surgeon’s personal 
views and patient characteristics influenced the extent of 
ND. In addition, the initial MRI reports often lacked spe-
cific information on the suspicious levels and number of 
lateral neck metastases, as well as of the possible extran-
odal extension (ENE). Thus, to standardize the reports, 
all studies were re-evaluated by an experienced head and 
neck radiologist (R.L.), who assessed the affected levels, 
and estimated the number of LNMs. These two reports were 
compared to show any interobserver difference. The imag-
ing data were compared level-by-level with histopathology 
from the ND preparate to determine their correlation. US 
was performed either in the referring institution, or at our 
institution (n = 27, 69%), and US data were also compared 
with histopathology level-by-level, when possible. Postop-
erative complications were classified according to the Cla-
vien–Dindo classification of surgical complications [15].
MRI
The MRI scans were performed on a 1.5 T (n = 32) or a 
3 T (n = 7) MRI scanner with a neck coil in different imag-
ing centres in the referral area using the following pulse 
sequences: axial fat-suppressed T2-weighted images, axial 
T1-weighted images, and gadolinium-enhanced fat-sup-
pressed axial and coronal T1-weighted images. Slice thick-
ness was 3 or 4 mm. These imaging sequences were required 
to be regarded as a high-quality and diagnostic MRI. In 
addition, axial fat-suppressed T1-weighted pre-gadolinium 
images were acquired in 33 patients to illustrate the possible 
increased T1 signal intensity.
A head and neck radiologist (R.L.) reviewed the MRI 
images in a blinded fashion, without knowledge of the 
specific histopathology from ND. A node was considered 
malignant if it demonstrated increased T1 signal inten-
sity (Fig. 1) or if: (1) the minimal diameter of the node 
exceeded 10 mm (11 mm for digastric nodes); or (2) it 
showed central necrosis (Fig. 2), ENE (Fig. 2) or cystic 
change (Fig. 3); or (3) it was round in shape (Fig. 4); or 
(4) nodes were fused (Figs. 1, 2, 3). In addition, small, 
Fig. 1  Fused, metastatic T1 hyperintense Level II lymph nodes. The 
minimal diameter of the largest node is 16  mm. Contrary to CT or 
US, MRI can identify increased T1 signal intensity indicating thy-
roglobulin
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clustered nodes were considered suspicious and rated as 
malignant (Fig. 4). A lymph node that involved two adja-
cent levels was rated to situate in the level that encom-
passed the largest volume. In the re-evaluation, criteria 
for ENE were: (1) presence of high-intensity signal in the 
tissues around the node on fat-suppressed T2-weighted 
images or (2) an irregular nodal margin.
Results
The study cohort consists of 39 patients operated for lateral 
LNM of PTC at our institution, and the baseline demograph-
ics are presented in Table 1. Re-evaluation of MRI scans did 
not change the estimate of the general distribution of LNMs.
By the time, PTC patients were sent to our department 
because of lateral LNM, and US had been performed 
already, thus limiting the number of preoperative US at our 
institution. The suspicious levels were unspecified in the US 
reports, because at our department, the aim of preoperative 
Fig. 2  Gadolinium-enhanced T1 weighted fat-saturated image of 
Level II fused nodes. The nodes enhance unevenly indicating cen-
tral necrosis and show enhanced edema in the surrounding soft tissue 
indicating extranodal extension
Fig. 3  T2 fat-saturated image of bilateral fused metastatic lymph 
nodes. On the left the larger lymph node aggregate exhibits multifocal 
cystic change and extends to Levels II, III, IV, and V
Fig. 4  Fat-saturated T2 coronal image with several small and clus-
tered lymph nodes in Level III on the left; some of the nodes are 
round in shape
Table 1  Baseline demographics of 39 patients with papillary thyroid 
carcinoma
n number, L level
Age, mean 45.5 years (range 18–82)
Gender; n (%) Women 23 (59)
Men 16 (41)
Previous cancer; n (%) No 34 (87)
Yes 5 (13)




Operation side; n (%) Right 20 (51)
Left 11 (28)
Bilateral 8 (21)
Levels of neck dissection;






Complications; n (%) No 22 (56)
Yes 17 (44)
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US is not to clarify the levels of LNMs. Thus, it was impos-
sible to retrospectively evaluate the number and levels of 
lymph nodes from US images, and comparison between US 
and MRI on these parameters was inhibited.
Study population was young with a mean age of 
45.5 years. The majority of patients were otherwise healthy, 
since 32 (82%) had ASA score 1–2 (Classification by Ameri-
can Association of Anesthesiologists) and CCI score 0–1 
(Charlson Comorbidity Index).
We compared the levels of LNMs in MRI with the his-
topathology of the lateral ND preparate level-by-level. 
All patients who had undergone lateral ND showed nodal 
metastases on histopathology. Because Levels III and IV 
are most commonly affected and basically always included 
in ND in these patients (in 97% of patients in this cohort), 
we focused on Levels II and V. As NDs were performed on 
levels with negative preoperative MRI findings (29 out of 
all 64 dissected levels, in 16% of Level II NDs and in 75% 
of Level V NDs), we had an opportunity to study both the 
true and false positives but also the true- and false-negative 
results of MRI (Table 2). Regarding Level II, there were 
12 (38%) patients with false-positive scans and one (3%) 
patient with false-negative scan. Regarding Level V, there 
were two (6%) patients with false-positive scans and three 
(9%) patients with false-negative scans. The three patients 
with false-negative MRIs for Level V presented with large 
bulky lateral LNMs. Their ND included Level V in all cases 
irrespective of the scan report. Furthermore, MRI seemed 
inadequate to assess ENE. Histopathology revealed ENE in 
24 (62%) patients, although MRI indicated it only in eight 
patients (21%; p = 0.39).
Seventeen patients experienced 18 postoperative compli-
cations. These were categorized according to Dindo et al. 
[15]. The most common postoperative complication was 
hypocalcemia (Grade I), seen in six patients (15%). Four 
patients (10%) experienced postoperative weakness of the 
accessory nerve (Grade Id). Neural function recovered 
completely in two patients in a median time of 5 months 
but persisted in two (5%). Three patients (7%) developed 
Horner’s syndrome (Grade Id). One patient (3%) had acute 
postoperative arterial bleeding (Grade IIIb), which required 
immediate re-operation. One patient (3%) developed chylus 
leak (Grade IIIb), which was managed operatively twice. 
One patient (3%) developed a postoperative seroma (Grade 
I), which required puncture. Two (5%) postoperative infec-
tions (Grade II) were treated with antibiotics. The follow-up 
time varied from 8 to 32 months (median, 13 months).
Discussion
The objective of the present study was to evaluate the abil-
ity of preoperative MRI to assess the distribution of lateral 
LNMs in patients with regionally metastatic PTC. MRI was 
fairly specific in diagnosing lateral LNMs for Level V, with a 
high negative predictive value. For Level II, MRI was highly 
sensitive but included many false positives in the present 
study. Occult metastases were more common at Level II 
(25%) than at Level V (13%).
We have regional management algorithm for patients with 
PTC. Patients are primarily treated at the Department of Sur-
gery. At our institution, we perform surgery for all patients 
with PTC with lateral neck metastases. US together with fine 
needle aspiration biopsy are used to diagnose the disease, 
preoperative MRI; however, we use for staging and surgi-
cal planning. Unlike US studies, dedicated head and neck 
radiologist performs most MRI studies at our institution, 
possibly also contributing to the results and highlighting the 
accuracy of our MRI reports.
According to the current management guidelines, CT and 
MRI are used as an adjunct to US for patients with PTC 
with clinical suspicion for advanced disease, including inva-
sive primary tumor, or clinically apparent multiple or bulky 
lymph node involvement [16]. Although iodine containing 
contrast agent should gradually disappear within 2 months, 
we favor MRI over CT at our institution to show possible 
lateral LNMs [16]. PTC patients in the present study were 
young, as also others have pointed out, although the mean 
age has slightly risen over the years [17]. Thus, MRI seems a 
more preferred method to avoid radiation dose in this patient 
Table 2  Correlation of preoperative MRI with histopathology to 
show the number of individual levels with pathological lymph nodes 
on the lateral neck in Level II (A), Level V (B), and the statistical 
correlates for MRI (C)
PPV positive predictive value, NPV negative predictive value, CI con-
fidence interval
a One patient excluded because of indefinite histopathology
MRI positive Histopathology malignant
Yes No Total
A. Level II
 Yes 15 12 27
 No 1a 3 4
 Total 16 15
B. Level V
 Yes 6 2 8
 No 3a 20 23
 Total 9 22
% Level II (95% CI) Level V (95% CI)
C. Accuracy of MRI
 Sensitivity 94 (70–100) 67 (30–93)
 Specificity 20 (4–48) 91 (71–100)
 PPV 56 (35–75) 75 (35–97)
 NPV 75 (19–99) 87 (66–97)
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population. In some patients, FDG-PET–CT may show addi-
tional value in evaluating regional or distant metastatic dis-
ease or recurrences, but its routine preoperative use is not 
recommended [18, 19].
We feel that our current MRI protocol (axial fat-satu-
rated T2-weighted, axial T1-weighted, axial fat-saturated 
T1-weighted, axial and coronal gadolinium-enhanced, fat-
saturated T1-weighted images) is sufficient and provides 
good quality for evaluation of the neck. Including pre-gado-
linium T1 fat-suppressed sequence allows identifying very 
small nodes containing thyroglobulin, which may be other-
wise overlooked. Although radiologists commonly opt out, 
reporting the suspected levels on MRIs may help the surgeon 
to guide the extent of ND, especially when considering omit-
ting surgery of inconclusive levels.
Prophylactic lateral ND is not generally recommended for 
patients with PTC [20, 21]. The extent of ND in regionally 
metastatic PTC remains unsettled due to the lack of prospec-
tive studies, but as “berry picking” increases the risk for 
recurrences, an agreement lies on some type of ND as the 
treatment of choice for LNM [14, 22–27]. Since LNMs are 
most commonly found at Levels III and IV, including these 
levels in ND has been recommended in every patient with 
suspected lateral LNM [27]. Others prefer including also 
Levels II and V because of the lack of sensitivity of preop-
erative imaging to define these areas [3]. On the contrary, 
some rely on preoperative imaging to guide the extent of 
ND with the intention to avoid complications related to dis-
secting Levels II B and V [8]. The extent of ND and related 
possible complications requires careful consideration due 
to the reverse risks of surgical and oncological morbid-
ity. Although patients with PTC are generally young with 
good overall survival, the risk for locoregional recurrences 
is known to be higher in patients with lateral LNMs [8]. 
Whether MRI can provide additional help in determining 
the extent of ND remains unsettled. Therefore, we aimed 
to assess both the rates of false-positive and false-negative 
findings in MRI, concentrating on the most discordant Lev-
els II and V.
In the present study, ND included Levels II and espe-
cially V more often than the preoperative MRI indicated. 
This is an advantage, as previous studies usually lack infor-
mation about the false-negative rate of imaging to assess 
neck metastases in PTC [28]. In our material, both clinical 
and pathological lateral LNMs were more common at Level 
II than at Level V. The limited number of patients undoubt-
edly affects the statistical results (Table 2). The ability of 
MRI to correctly indicate the presence of pathological lymph 
nodes was 56% for Level II and 75% for Level V. Likewise, 
the negative predictive value was higher for Level V (87%) 
than for Level II (75%). MRI’s sensitivity was 94% in Level 
II compared with 67% in Level V. This difference is prob-
ably attributable to the criteria for interpreting the imaging 
reports: the three patients with false-negative MRI scans 
for Level V had bulky nodal mass on the lateral neck, but 
the largest volume was categorized to be located either at 
Level III or at Level IV on imaging, and were thus regarded 
as nodes of either of these levels. As for Level II, 12 false-
positive findings led to relatively low specificity (20%) and 
positive predictive value (56%) of MRI. Based on these 
findings, although it seems putatively appropriate to utilize 
preoperative MRI to omit Level V ND, this needs to be con-
firmed in larger cohorts before changing general practice 
and guidelines. On the contrary, using preoperative MRI to 
assess the probable inclusion/exclusion of Level II in ND 
seems unjustifiable, as we had a fairly high number of false-
positive cases at this level. In our cohort, however, Level II 
was not subdivided into A and B in all cases in the patho-
logical analysis. Still, routine dissection of Level II B would 
most likely be exaggeration and increase complications.
We showed that ENE was common and diagnosed after 
ND in 62% of patients, similar to that published by Lee et al. 
[29], but preoperative MRI indicated it only in 33% of them. 
In squamous cell carcinoma (SCC) of the head and neck, 
MRI seems to underestimate the occurrence of ENE [30, 
31]. Steinkamp et al. reported sensitivity of 74% and speci-
ficity of 72% for MRI in detecting ENE, while the false-
negative rate was 33% in the study by Shaw et al. [30, 31]. 
Similar to SCC [32], ENE is an independent predictor for 
locoregional recurrence in PTC [33–35] even in patients less 
than 45 years of age [36], but shows no clear impact on dis-
ease specific survival [35]. The follow-up time in the present 
study was too short to make conclusions about survival, but 
based on the literature, it seems that ENE in PTC does not 
compromise overall survival in contradiction to SCC [32] 
of the head and neck.
Our complication rate was 44%, of which only 5% repre-
sented Grades III–IV [15]. Including Levels II B and V in 
ND increases the risk for accessory nerve injury [22], which 
can cause additional discomfort and diminished quality of 
life [37]. In our cohort, spinal accessory nerve dysfunction 
occurred in the three patients with bulky lateral neck mass 
and with clinically negative MRI scans for Level V, and in 
one patient with clinically positive nodes at Level V. In these 
patients, ND of Level V was inevitable. Neural dysfunction 
remained in two (5%) of them, which is in line with that 
presented by Glenn et al. [38]. Thus, based on our limited 
number of patients, ND of Level V increases the risk for 
neuropathic morbidity in patients with lateral LNMs, and 
omitting this level would be most desirable when onco-
logically possible. Horner’s syndrome developed in three 
patients (7%), which is comparable to the literature [39–41].
This study presents with limitations due to the retrospec-
tive design. The number of patients was limited to draw 
definite conclusions on omitting ND on specific levels. 
In addition, patients had only a short follow-up time. The 
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re-evaluation of all preoperative MRIs to standardize the 
scans may be regarded as strength in this study. Only com-
parable MRI sequences were included in this study.
Conclusions
In this patient cohort, preoperative MRI was fairly accurate 
to assess the distribution of positive LNMs on the lateral 
neck—especially regarding Level V—in patients with PTC, 
although the ability to show ENE was low. It seems that pre-
operative MRI may help to perform a more targeted lateral 
ND in the primary treatment setting, although the number 
of patients in the present study was too limited to draw any 
definite conclusions on possibly omitting ND on specific 
levels. MRI showed more false positives and more occult 
metastases at Level II than at Level V, and in general, Level 
V was less often involved with LNMs. We suggest conduct-
ing imaging studies in the future with more patient data to 
accomplish targeted surgical fields and minimal surgical 
morbidity in this patient group.
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